Related Site Contact Us Site Map Chinese vesion
News Introduction Admimmune in History Upcoming product Recruit
News  
2008/11/1 Mr. Ignatius Wei has been appointed as the Deputy C.E.O. of Adimmune Corp.
2008/6/30 Dr. Chi Steve Chan honored to be the Chairman of Adimmune
2005/10/19 ADImmune Recognized in Vaccines Market with 2005 Growth Strategy Leadership Award
Introduction  
 
¡@¡@ADImmune Corporation, otherwise called ¡§Kuo Kwang Biotechnology Company¡¨, formerly Kuo Kwang Serum and Vaccine Laboratories, was founded in 1965 through the technical support of the Kitasato Institute, one of the biggest developers and producers of vaccines in Japan. ADImmune is the only human vaccine manufacturer in Taiwan. Under strict cGMP regulations, ADImmune produces Japanese encephalitis vaccine (JEV) and tetanus toxoid. The former item commands 100% of the local market while the later occupied 50% of the market.

¡@¡@In 1997, ADImmune doubled its capital and brought in new management to meet with new financial, technical and regulatory needs. With several new candidates in the product pipeline, ADImmune is actively looking for advanced technologies in the development and production of biologics for disease prevention and treatment.

¡@¡@Since 1998, ADImmune received grants from the Ministry of Economic Affairs to develop new technology and products, including the new production process of JEV, using kidney cell line from African Green Monkey as a vehicle under a serum-free cell growth condition. The clinical trials are scheduled to begin in 2008. Another major program focused by the company is the platform technology of ¡§DNA Vaccine¡¨. ADImmune has established a collaboration program with the Developmental Center for Biotechnology and other research institues in Taiwan, to develop plasmid DNA manufacturing processes. In one of the projects that uses JEV DNA vaccine as a working model, preliminary mice studies have been completed with promising results. ADImmune believes that Japanese encephalitis being an East Asian epidemic receives little attention from mainstream pharmaceutical companies in the West. Therefore ADImmune stands a good chance of becoming a major supplier of superior quality JEV product worldwide.

¡@¡@Recently the Executive Yuan Development Fund, a major government investment program, has invested directly into ADImmune with NT$512 million (US$16 million) as a sign of support that is equal to approximately 21% of post-money stake. The money will be used to build up a state-of-the-art cGMP level manufacturing plant for vaccine production and plasmid DNA contract manufacturing business.

¡@¡@The Company has a factory in central Taiwan with over 10,000 square feet of GMP facilities at present. There are over 70 employees with advanced education and experience. Dr. Sy-Dar Wang CTO, has a long credential in the vaccine business and other US companies, Dr. C.C Chang held senior R&D and management position in Lederle Labs.

Welcome to ADIMMUNE.